IRONWOOD PHARMACEUTICALS INC Logo

IRONWOOD PHARMACEUTICALS INC

A healthcare company developing and commercializing therapies for GI diseases.

IRWD | US

Overview

Corporate Details

ISIN(s):
US46333X1081
LEI:
Country:
United States of America
Address:
100 SUMMER STREET, SUITE 2300, 2110 BOSTON

Description

Ironwood Pharmaceuticals is a gastrointestinal (GI)-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for patients. The company's core activities involve the development and commercialization of innovative therapies that target GI conditions. Its primary commercial product, LINZESS® (linaclotide), is a prescription medication for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Leveraging its singular focus and deep expertise in the GI field, Ironwood Pharmaceuticals also maintains a pipeline of potential new treatments to address significant unmet patient needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-07 17:05
4
English ZIP 6.7 KB
2026-01-05 22:41 English ZIP 6.8 KB
2026-01-02 13:05
FORM 8-K
English ZIP 128.7 KB
2025-12-23 13:06
FORM 8-K
English ZIP 104.4 KB
2025-12-17 22:05
4
English ZIP 8.0 KB
2025-11-26 13:00
FORM 8-K
English ZIP 64.7 KB
2025-11-19 22:05
4
English ZIP 6.8 KB
2025-11-14 22:05 English ZIP 6.9 KB
2025-11-10 13:12
FORM 8-K
English ZIP 167.6 KB
2025-11-10 13:01
10-Q
English ZIP 1.6 MB
2025-10-10 13:05
FORM 8-K
English ZIP 64.8 KB
2025-09-18 02:28
4
English ZIP 7.7 KB
2025-09-03 22:05
FORM 8-K
English ZIP 65.2 KB
2025-08-15 18:26 English ZIP 9.9 KB
2025-08-13 22:05
4
English ZIP 6.8 KB

Automate Your Workflow. Get a real-time feed of all IRONWOOD PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IRONWOOD PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IRONWOOD PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.